DOI: 10.12890/2024_004237

A case of polyserositis, chylous ascites and hepatitis induced by immune checkpoint-inhibitors

Authors

  • Marta Castelli Department of Oncology and Hematology, University of Milan and ASST Papa Giovanni XXIII, Bergamo, Italy
  • Mauro Betelli Internal Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Anna Valenti Internal Medicine Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Barbara Merelli Oncology Unit, ASST Papa Giovanni XIII, Bergamo, Italy
  • Alessandro Loglio Gastroenterology, Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Mauro Viganò Gastroenterology, Hepatology and Transplantation Unit, ASST Papa Giovanni XXIII, Bergamo, Italy
  • Alberto Benetti Internal Medicine Unit, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy

mbetelli@asst-pg23.it

Keywords

Immune-related adverse events, cancer, immune checkpoint inhibitors, immunotherapy

Abstract

We describe a rare case of polyserositis with chylous ascites following nivolumab therapy, highlighting the challenges in recognizing and managing immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICPIs).

View the entire article

Downloads

References

  1. Johnson PC, Gainor JF, Sullivan RJ, Longo DL, Chabner B. Immune checkpoint inhibitors – the need for innovation. N Engl J Med 2023;388:1529–1532.
  2. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 2016;54:139–148.
  3. Zierold S, Akcetin LS, Gresser E, Maier AM, König A, Kramer R, et al. Checkpoint-inhibitor induced polyserositis with edema. Cancer Immunol Immunother 2022;71:3087–3092.
  4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
  5. Lescure C, Lescoat A, Salé A, Bazin Y, Duvergé L, Desrues B, et al. Systemic capillary leak syndrome (Clarkson’s disease) as a complication of anti-programmed death 1 immunotherapy. J Thorac Oncol 2019;14:e131–e132.
  6. Polishchuk I, Yakobson A, Zemel M, A Sharb A, Shalata W, Rosenberg E, et al. Nivolumab-induced systemic capillary leak syndrome as an ultra rare life-threatening phenomenon of late toxicity and intravenous immunoglobulin efficacy. Immunotherapy 2021;13:807–811.
  7. Qin H, Vlaminck B, Owoyemi I, Herrmann SM, Leung N, Markovic SN. Successful treatment of pembrolizumab-induced severe capillary leak syndrome and lymphatic capillary dysfunction. Mayo Clin Proc Innov Qual Outcomes 2021;5:670–674.
  8. Neuville C, Aubin F, Puzenat E, Popescu D, Crepin T, Nardin C. Nivolumab-induced capillary leak syndrome associated with chylothorax in a melanoma patient: a case report and review of the literature. Front Oncol 2022;12:1032844.
  9. Haslam A, Prasad V. Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs. JAMA Netw Open 2019;2:e192535.

Published

2024-05-31

Issue

Vol. 11 No. 7 (2024)

Categories

How to Cite

1.
Castelli M, Betelli M, Valenti A, Merelli B, Loglio A, Viganò M, et al. A case of polyserositis, chylous ascites and hepatitis induced by immune checkpoint-inhibitors. EJCRIM [Internet]. 2024 May 31 [cited 2026 Nov. 3];11(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/4237

Most read articles by the same author(s)